BCIQ Profiles

Company Profile ReportTarget Profile Report

Samsung Bioepis, AbbVie settle Humira biosimilar dispute

Samsung Bioepis Co. Ltd. and AbbVie Inc. (NYSE:ABBV) agreed to settle all litigation related to AbbVie's Humira adalimumab in a deal that will allow Samsung Bioepis to launch its biosimilar

Read the full 304 word article

How to gain access

Continue reading with a
two-week free trial.